CEACAM6 Mouse anti-Human, Clone: 439424, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA524164
In direct ELISAs and Western blots, no cross-reactivity with recombit human CEACAM-1, -3, or -5 is observed. Reconstitute at 0.5 mg/mL in sterile PBS.CEACAM1 (BGP/CD66a) is a transmembrane glycoprotein which belongs to the carcinoembryonic antigen (CEA) gene family. It is expressed on cells of epithelial and myeloid origin and mediates homophilic intercellular interactions that influence cellular growth, immune cell activation, and tissue morphogenesis. CEACAM1 is a putative tumour suppressor based on diminished expression in some aggressive types of cancer cells. The anti-tumour effect may be due to inhibition of tumour angiogenesis, possibly by increased secretion of anti-angiogenic molecules from the cells. Like all members of the CEACAM family, it consists of a single N domain, with structural homology to the immunoglobulin variable domains, followed by two immunoglobulin constant-like A (A1, A2) and one B domain. While the N, A1 and B domains can also be found in other CEA-family members, the A2 domain of CEACAM1 differs from those found in other CEACAM.
|PBS with 5% trehalose and No Preservative|
|pan CEACAM, Carcinoembryonic antigen-related cell adhesion molecule 1, BGP, BGP-1, CD66a, Biliary glycoprotein 1, Carcinoembryonic antigen-related cell adhesion molecule 3, CD66d, Carcinoembryonic antigen CGM1, CGM1, Carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e, Carcinoembryonic antigen-related cell adhesion molecule 6, CD66c, NCA, CEACAM-1, CEACAM-3, CEACAM-5, CEACAM-6|
|-20° C, Avoid Freeze/Thaw Cycles|
|Flow Cytometry, Western Blot|
|Mouse myeloma cell line NS0-derived recombit human CEACAM-6/CD66c Lys35-Gly320|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok